Clinical Trial Update: Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma [NA]

View source ↗

Summary

A clinical trial evaluating sorafenib plus aspirin to prevent recurrence in high-risk hepatocellular carcinoma patients has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Aspirin (Aspirin)
• Nexavar (sorafenib) (sorafenib)

Snippet

Sponsor: Fudan University | Conditions: Hepatocellular Carcinoma | NA | Status: TERMINATED